Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo , but not from depressive recurrences .
Add-on or monotherapy paliperidone palmitate in SAD patients  protected from psychotic , depressive , and manic symptoms .
In patients with BD-I with a manic episode at study enrolment , aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes .
LAIs  are effective and well-tolerated maintenance treatments for BD and SAD .
They showed better efficacy in preventing mania than depression .
LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems
Long-Acting Injectable Antipsychotics ( LAIs ) are used to overcome non-compliance in psychoses , mainly schizophrenia spectrum disorders .
We aim ed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder ( BD ) and /or Schizoaffective Disorder ( SAD ) .
A Pilot, 15-month, randomised effectiveness trial of Risperidone long-acting injection (RLAI) versus oral atypical antipsychotic agents (AAP) in persons with bipolar disorder.
UNLABELLED Chengappa KNR , Turkin SR , Schlicht PJ , Murphy SL , Brar JS , Fagiolini A , Houck PR , Garbutt RG , Fredrick N. A Pilot , 15-month , r and omised effectiveness trial of Risperidone long acting injection ( RLAI ) versus oral atypical antipsychotic agents ( AAP ) in persons with bipolar disorder . OBJECTIVE Long-acting injectible antipsychotic agents are rarely considered in the treatment of bipolar patients [ bipolar disorder ( BPD ) ] . We posited that BPD patients receiving risperidone long-acting injections  [ Risperidone long-acting injections ( RLAIs ) ] would experience fewer negative clinical events than those receiving oral atypical antipsychotic agents ( AAP ) . METHODS Adult BPD patients in a hypomanic , manic or mixed episode were r and omised to either oral risperdone followed by RLAI ( n = 23 ) or an AAP ( n = 25 ) for 15 months . Any mood stabilizers were continued . An independent clinician board declared any clinical events that occurred but the treatment assignment was concealed . RESULTS Nine of the 48 patients who participated in this study did not improve , leaving 39 patients in 1-year extension . RLAI patients received the following bi-weekly dosages : 25 mg ( n = 9 ) , 37.5 mg ( n = 8) , and 50 mg ( n = 6 ) . The AAP group included aripiprazole ( n = 11 , 15 - 30 mg/day ) , quetiapine ( n = 8 , 300 - 700 mg/day ) , olanzapine ( n = 5 , 15 - 25 mg/day ) , and ziprasidone , ( n = 1 , 160 mg/day ) . In total , 47 clinical events were declared . The RLAI-treated group experienced significantly fewer clinical events ( mean : 0.86 ± 0.73 ) compared with the AAP group ( 1.61 ± 1.29 ) , t = 2.29 , d.f . = 37 , p = 0.028 ( 95 % CI = 0.087 - 1.421 ) . Of all , 50 % of the AAP subjects gained ≥ 7 % of their baseline body weight as did 38 % of the RLAI-treated patients . CONCLUSIONS RLAI-treated patients experienced significantly fewer negative clinical events . Further exploration should focus on which subtypes of BPD patients might benefit from RLAI treatment . Weight gain in BPD subjects requires clinical attention . Limitations include an open design , small sample size and the inability to conclude on whether this strategy is useful for depressive episodes
Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo , but not from depressive recurrences .
Add-on or monotherapy paliperidone palmitate in SAD patients  protected from psychotic , depressive , and manic symptoms .
In patients with BD-I with a manic episode at study enrolment , aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes .
LAIs  are effective and well-tolerated maintenance treatments for BD and SAD .
They showed better efficacy in preventing mania than depression .
LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems
Long-Acting Injectable Antipsychotics ( LAIs ) are used to overcome non-compliance in psychoses , mainly schizophrenia spectrum disorders .
We aim ed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder ( BD ) and /or Schizoaffective Disorder ( SAD ) .